A Phase II Study of CT-2584 Mesylate in Patients With Hormone Refractory Prostate Cancer
OBJECTIVES: I. Compare the efficacy, safety, and pharmacokinetics of 2 different treatment
schedules of CT-2584 in patients with hormone refractory, metastatic adenocarcinoma of the
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2
treatment arms: Arm I: Patients receive CT-2584 IV over 6 hours daily for 3 days every 3
weeks. Arm II: Patients receive CT-2584 IV over 6 hours once every 7 days for 3 weeks.
Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: Approximately 80 patients will be accrued for this study.
Allocation: Randomized, Primary Purpose: Treatment
Carolyn Paradise, MD
United States: Federal Government
|Jonsson Comprehensive Cancer Center, UCLA||Los Angeles, California 90095-1781|
|Johns Hopkins Oncology Center||Baltimore, Maryland 21287|
|University of Washington Medical Center||Seattle, Washington 98195-6043|
|UCSF Cancer Center and Cancer Research Institute||San Francisco, California 94115-0128|
|Herbert Irving Comprehensive Cancer Center||New York, New York 10032|
|Our Lady of Mercy Medical Center||Bronx, New York 10466|
|Stanley Scott Cancer Center||New Orleans, Louisiana 70112|